{
    "clinical_study": {
        "@rank": "144733", 
        "acronym": "MERIBEL", 
        "arm_group": {
            "arm_group_label": "monotherapy treatment with Eribulin", 
            "arm_group_type": "Experimental", 
            "description": "Eribulin Dosage: 1.4 mg/m2 Route of administration: IV bolus Schedule of cycle: D1 and D8 every 21 days"
        }, 
        "brief_summary": {
            "textblock": "Multicentre, prospective, non-controlled phase II clinical trial to evaluate the efficacy\n      and tolerability of first line single agent Eribulin in patients with HER2-negative\n      metastatic breast carcinoma previously exposed to taxanes for early stage.\n\n      The primary objective of the study is to determine the median time to progression achieved\n      with Eribulin. Other secondary objectives will be; overall response rate, clinical benefit\n      rate, time to treatment progression, duration of response and toxicity profile."
        }, 
        "brief_title": "Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Breast Neoplasm", 
            "Metastasis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Neoplasms", 
                "Neoplasm Metastasis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed metastatic breast cancer HER2 negative, stage IIIb/IV\n\n          -  Previous history of early disease (stage I-IIIb), surgically resected and treated\n             with standard chemotherapy for at least 12 weeks at which included a taxane or\n             ixabepilone\n\n          -  Patients must have progressed in the 36 months after treatment with taxanes  or\n             ixabepilone.\n\n          -  Age \u2265 18 years\n\n          -  Given written informed consent\n\n          -  Index of Eastern Cooperative Oncology Group (ECOG) of 0 or 1\n\n          -  Patients must have recovered from toxicities related with previous treatment   (CTC \u2265\n             1)\n\n          -  Measurable or evaluable disease (RECIST 1.1)\n\n          -  Adequate bone marrow function\n\n          -  Adequate hepatic function\n\n          -  Adequate renal function\n\n          -  Life expectancy \u2265 3 months\n\n        Exclusion Criteria:\n\n          -  Breast cancer patients initially diagnosed with local disease advanced or metastatic\n             disease.\n\n          -  Patients who have previously received cytotoxic therapy Hormone therapy permitted if\n             the patients have interrupted it at least two weeks before the start of the study\n             treatment.\n\n          -  Major surgery or significant traumatic injury during the 4 weeks prior to study\n             treatment or patients who may require major surgery during the assay.\n\n          -  Brain metastases or leptomeningeal uncontrolled.\n\n          -  Serious medical condition and / or not properly controlled (unstable angina, lung\n             function severe impaired, uncontrolled diabetes, active serious infection,liver\n             disease, HIV seropositivity, active bleeding diathesis)\n\n          -  Other malignancies in the last three years, except: cervical carcinoma in situ, basal\n             cell carcinoma or squamous cell skin carcinoma,that have been properly treated\n\n          -  Patients who are pregnant or breastfeeding, or adults with reproductive capacity wich\n             are not using effective contraception.\n\n          -  Patients receiving chronic treatment with systemic corticosteroids or other\n             immunosuppressive drugs (except corticosteroids with a daily dose equivalent to\n             prednisone \u2264 20mg on a stable dose regimen one minimum of 4 weeks prior to study\n             entry. Topical and inhaled corticosteroids are allowed\n\n          -  Active alcoholism or drugs addiction documented.\n\n          -  Prior history of noncompliance with medical regimens\n\n          -  Patients who do not want or can not comply with the study protocol"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02061085", 
            "org_study_id": "OBU-SW-H-02"
        }, 
        "intervention": {
            "arm_group_label": "monotherapy treatment with Eribulin", 
            "intervention_name": "Eribulina", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Breast Neoplasm Metastasis", 
            "Receptor,HER-2", 
            "Eribulin", 
            "Furans, quetones", 
            "Antimitotic agent"
        ], 
        "lastchanged_date": "February 11, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Zaragoza", 
                        "country": "Spain", 
                        "state": "Arag\u00f3n"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oviedo", 
                        "country": "Spain", 
                        "state": "Asturias"
                    }
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salamanca", 
                        "country": "Spain", 
                        "state": "Castilla y Le\u00f3n"
                    }
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "state": "Catalu\u00f1a"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Badajoz", 
                        "country": "Spain", 
                        "state": "Extremadura"
                    }
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "La Coru\u00f1a", 
                        "country": "Spain", 
                        "state": "Galicia"
                    }
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Palma de Mallorca", 
                        "country": "Spain", 
                        "state": "Illes Balears"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gran Canaria", 
                        "country": "Spain", 
                        "state": "Islas Canarias"
                    }
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pamplona", 
                        "country": "Spain", 
                        "state": "Navarra"
                    }
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain"
                    }
                }, 
                "status": "Active, not recruiting"
            }
        ], 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase IIa Prospective, Multicenter, Open and Not Controlled of the Efficacy and Tolerability on the First Line Treatment With Eribulin as a Unic Agent on Patients With HER2 Negative Metastatic Breast Cancer Previously Treated With Taxanes", 
        "overall_contact": {
            "email": "duna.zaragoza@medsir.org", 
            "last_name": "Duna Zaragoza"
        }, 
        "overall_official": {
            "affiliation": "Valencia", 
            "last_name": "Antonio Llombart, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Spain: Spanish Agency of Medicines", 
                "Spain: Ethics Committee"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Median time to disease progression and treatment benefit variable", 
            "safety_issue": "No", 
            "time_frame": "Up to two years from the last dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02061085"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Objective response rate", 
                "safety_issue": "No", 
                "time_frame": "Up to one year from the first dose"
            }, 
            {
                "measure": "Clinical benefit rate", 
                "safety_issue": "No", 
                "time_frame": "Up to one year from the first dose"
            }, 
            {
                "measure": "Time until progression after the treatment", 
                "safety_issue": "No", 
                "time_frame": "Up to two years from the last dose"
            }, 
            {
                "measure": "Median duration of response", 
                "safety_issue": "No", 
                "time_frame": "Up to one year from the first dose"
            }, 
            {
                "measure": "Safety of eribulin in terms of adverse reactions", 
                "safety_issue": "Yes", 
                "time_frame": "Up to two years form the last dose"
            }, 
            {
                "measure": "Utility functional hepatic levels as criteria for dose modifications instead of the Child-Pugh classification system for the assessment of liver involvement", 
                "safety_issue": "No", 
                "time_frame": "Up to one year form the last dose"
            }
        ], 
        "source": "Medica Scientia Innovation Research", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Medica Scientia Innovation Research", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}